Study objectives To evaluate the efficacy and tolerability of levofloxacin (L) as monotherapy
in patients with severe community-acquired pneumonia (CAP) in comparison with therapy …

Background Levofloxacin, an antibiotic from the quinolone family, which is used with
success in the ambulatory treatment of patients with community-acquired pneumonia, has …

Study objectives To compare the efficacies of 10-day regimens of grepafloxacin
(GFX)(Raxar or Vaxar; Glaxo Wellcome; Greenford, UK), 600 qd, and clarithromycin …

Background: Macrolides and fluoroquinolones are frequently used for the empiric treatment
of community-acquired pneumonia (CAP). Objective: The aim of the study was to compare …

Background Community acquired pneumonia (CAP) is a major cause of morbidity,
hospitalization, and mortality worldwide. Management of CAP for many patients requires …

Most guidelines for the management of hospitalized patients with community-acquired
pneumonia (CAP) recommend commencing therapy with intravenous antibiotics, primarily …

Background Community‐acquired pneumonia (CAP) is a lung infection that can be acquired
during day‐to‐day activities in the community (not while receiving care in a hospital) …

To achieve best outcomes for their patients, physicians must be actively comparing their
outcomes against other institutions and not rely on historical data. A bundle of care that …

Delafloxacin is a novel fluoroquinolone with activity against Gram-positive, Gram-negative,
and atypical pathogens, including fluoroquinolone-nonsusceptible methicillin-resistant …

Objectives Guidelines recommend dual-therapy consisting of a β-lactam/macrolide (BLM) for
hospitalized patients with community-acquired pneumonia. Nevertheless, the superiority …